| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | - | 86,727 | 129,390 | 80,380 |
| Research and development | 720,973 | 791,581 | 993,475 | 1,046,693 |
| General and administrative | 553,299 | 651,721 | 463,736 | 493,102 |
| Total costs and expenses | 1,274,272 | 1,443,302 | 1,457,211 | 1,539,795 |
| Loss from operations | -1,274,272 | -1,356,575 | -1,327,821 | -1,459,415 |
| Interest income, net | 20,194 | 29,089 | 21,298 | 14,778 |
| Total other income/(expense) | 20,194 | 29,089 | 21,298 | 14,778 |
| Loss before income taxes | -1,254,078 | -1,327,486 | -1,306,523 | -1,444,637 |
| Provision for income taxes | - | 0 | - | - |
| Net loss | -1,254,078 | -1,327,486 | -1,306,523 | -1,444,637 |
| Basic | -0.28 | -0.31 | -0.64 | -1.29 |
| Basic | 4,549,120 | 4,305,243 | 2,056,804 | 1,119,129 |
| Dilutive | -0.28 | -0.31 | -0.64 | -1.29 |
| Dilutive | 4,549,120 | 4,305,243 | 2,056,804 | 1,119,129 |
LIPELLA PHARMACEUTICALS INC. (LIPO)
LIPELLA PHARMACEUTICALS INC. (LIPO)